

## **Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC**

**Leuven, BELGIUM – July 22, 2025 – 06:00 PM CET - [Oxurion NV](#)** (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation<sup>1</sup> it has received a transparency notification as follows:

Oxurion received a transparency notification on July 18, 2025, from Atlas Special Opportunities II, LLC indicating that as of July 16, 2025, it held 2,460,942 shares of the then outstanding 12,428,021 shares, and therefore crossed under the threshold (20%) by virtue of the selling of voting securities.

### **About Oxurion**

Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical group in transition, combining therapeutic innovation with technologies applied to clinical research. Through its rapidly expanding technology division, Oxurion is building integrated expertise around clinical data, with the ambition to accelerate, secure, and transform the processes involved in developing new treatments. The Group's headquarters are based in Leuven, Belgium. More information is available at [www.oxurion.com](http://www.oxurion.com).

### ***Important information about forward-looking statements***

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

### **For further information please contact:**

<p><u>Oxurion NV</u> Pascal Ghoson Chief Executive Officer <a href="mailto:Pascal.ghoson@oxurion.com">Pascal.ghoson@oxurion.com</a></p>
---

---

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

## ANNEX 1

<b>FSMA</b> FINANCIAL SERVICES AND MARKETS AUTHORITY	<b>Transparency notification</b> Form TR-1 BE <b>PART I</b>
--	---

### 1) Status of the notification

Final

### 2) Issuer

Name OXURION  
Identification number 0881-620-624

### 3) Reason for the notification

Acquisition or disposal of voting securities or voting rights

+

### 4) Notification by

A person that notifies alone

+

### 5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities II LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

+

### 6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

+

Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

### 7) Date on which the threshold is crossed

16/07/2025 (DD/MM/YYYY)

### 8) Threshold that is crossed (in %)

20

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

### 9) Denominator

12,428,021

Please enter the denominator before filling in the data


### 10) Notified details

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Holders of voting rights					
Atlas Special Opportunities II LLC	2,751,917	2,460,942		19.80%	
TOTAL		2,460,942	0	19.80%	0.00%

+

Start with "groups" of holders. Add subtotals with  $\Sigma$ , and then finish with the persons who are "alone".  
For groups, start with the ultimate controlling natural person or legal entity.  
The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial instruments						
Holders of equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0.00%	

 The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)	# of voting rights	% of voting rights
	CALCULATE	2,460,942
		19.80%

#### 11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities II LLC is not a controlled entity.

#### 12) In case of proxy voting for only one GM

Holder  will cease to hold / will hold again  0 voting rights as of  (DD/MM/YYYY)

#### 13) Additional information

On 10 July 2025 (with settlement date on 14 July 2025), Atlas Special Opportunities II LLC sold 361,664 shares in Oxurion NV, as a result of which its shareholding decreased to 2,751,917 shares (= 22.14%, denominator = 12,428,021).  
On 11 July 2025 (with settlement date on 15 July 2025), Atlas Special Opportunities II LLC sold 231,999 shares in Oxurion NV, as a result of which its shareholding decreased to 2,519,918 shares (= 20.28%, denominator = 12,428,021).  
On 14 July 2025 (with settlement date on 16 July 2025), Atlas Special Opportunities II LLC sold 58,976 shares in Oxurion NV, as a result of which its shareholding decreased to 2,460,942 shares (= 19.80%, denominator = 12,428,021).

Done at  New York

On  18/07/2025 (DD/MM/YYYY)

Name & capacity  Patrick Vancie, Proxyholder

Signature

Signed by:  
  
DN:CN=Patrick Vancie

For security reasons, the unsigned form in xlsx format should be transmitted to [trp.fin@fsma.be](mailto:trp.fin@fsma.be). You can do this manually OR if you have MS Outlook at your disposal via the "Save & Send" button.

In addition, a signed copy in PDF format should also be transmitted.